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Abstract
For the transmissible, neurogenerative family of prion diseases, few human models of infection exist and none
represent structured neuronal tissue. Human cerebral organoids are self-organizing, three-dimensional brain tissues
that can be grown from induced pluripotent stem cells. Organoids can model aspects of neurodegeneration in
Alzheimer’s Disease and Down’s Syndrome, reproducing tau hyperphosphorylation and amyloid plaque pathology.
To determine whether organoids could be used to reproduce human prion infection and pathogenesis, we
inoculated organoids with two sporadic Creutzfeldt-Jakob Disease prion subtypes. Organoids showed uptake,
followed by clearance, of the infectious inoculum. Subsequent re-emergence of prion self-seeding activity indicated
de novo propagation. Organoid health assays, prion titer, prion protein electrophoretic mobility and
immunohistochemistry demonstrated inoculum-specific differences. Our study shows, for the first time, that cerebral
organoids can model aspects of human prion disease and thus offer a powerful system for investigating different
human prion subtype pathologies and testing putative therapeutics.
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Introduction
The transmissible, neurodegenerative prion diseases affect
humans and animals. Acquired prion diseases arise due to
exposure to prion contaminated material. However, prion
diseases more often occur sporadically or due to hereditary
mutations within the gene encoding the prion protein
(PrP). In cases of human sporadic Creutzfeldt-Jakob Dis-
ease (sCJD), different molecular subtypes of prions have
been recognized [4, 13, 16, 32, 33] that influence the
clinical and pathological disease phenotypes. These sub-
types are identified by the electrophoretic mobility pattern
of the disease-associated, protease-resistant prion protein
(PrPRes) and by a genetic polymorphism at amino acid resi-
due 129, which may be a methionine or valine. The hetero-
geneity of the human subtypes and the brain regions they
target [39] causes complications when attempting to model
human diseases in cell models as homogenous cell systems
cannot address different neuronal vulnerabilities.
There are further challenges associated with investigat-
ing human prion diseases in vitro. First and foremost,
human cell lines have traditionally proven refractive to
prion infection. Only two cell models of prion infection
and propagation have been described that express nor-
mal human PrP levels in a human cellular background.
The first, published in 1995, reported stable CJD infec-
tion in sub-clones from the Sh-SY5Y neuroblastoma cell
line [19] but no further use of this model has ever been
reported. Recently, the second showed that astrocytes
differentiated from human induced pluripotent stem
cells (hu-iPSCs) can take up and propagate prion infection
from sCJD samples [18]. Uptake of infection by these as-
trocytes was influenced by sCJD subtype and residue 129
polymorphism (M or V) of both the host cells and the in-
ocula. This is the first fully human cell model developed
since the 1995 Sh-SY5Y study, and the only human model
of infection currently reported. Despite the significant ad-
vancement this model offers, it does not allow for studying
how human neurons respond to infection or for investi-
gating potential three-dimensional cellular cross-talk.
Hu-iPSCs have also been used to produce three-dimen-
sional, highly organized cerebral tissues; referred to as
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cerebral organoids [20, 35]. Cerebral organoids display
self-organization that generates an organ-like configuration
and, following the development of cortex neuronal popula-
tions, also populate with astrocytes and oligodendrocytes
creating the closest in vitro model of human brain tissue
yet described [20, 25, 35]. Organoids also develop func-
tional electrical signaling and can survive in culture for
many months; some may survive years [20, 44]. Cerebral
organoids have demonstrated substantial potential for mod-
elling developmental diseases, such as the microcephaly as-
sociated with Zika virus infection [21, 38]. Plus, their
longevity permits their use for investigating brain diseases
that develop over a longer time frame. For example, orga-
noids exhibit the tau hyperphosphorylation plus amyloid
deposition associated with Alzheimer’s Disease and Down’s
syndrome dementia [14].
Organoids or neuronal cultures from hu-iPSCs have
similarly been used to model prion dysfunction in cells
from people who are predisposed to developing prion dis-
ease due to mutations within the prion gene [14, 26].
Organoids generated from a patient carrying a Y218N PrP
mutation (that causes Gerstmann-Sträussler-Scheinker
prion disease) were able to reproduce certain pathological
changes, such as astrogliosis and tau hyperphosphoryla-
tion, but did not replicate PrPRes production [26]. We hy-
pothesized that, in addition to their use modeling genetic
prion diseases, cerebral organoid cultures could be used
to develop an in vitro human model of prion infection in
organized neuronal tissue by exposing them to sCJD
prions. In this study we found that human cerebral orga-
noids are susceptible to prion infection. Uptake of infec-
tion was influenced by the infecting inocula and the de
novo prions produced were influenced by the underlying
organoid. We conclude that human cerebral organoids
offer a new three-dimensional, neuronal tissue model of
human prion disease.
Materials and methods
Human induced pluripotent stem cells and culture
KYOU-DXR0109B (ACS-1023; ATCC) hu-iPSCs were
routinely cultured on low growth factor Matrigel (Roche)
in mTeSR1 medium (Stem Cell Technologies) with 5%
CO2 in a humidified incubator as described in the mTeSR
handbook. Colonies were passaged at approximately
70–80% confluency before colonies had started to con-
tact each other.
Human cerebral organoid generation and routine culture
Cerebral organoids were generated as described in Lan-
caster and Knoblich [20]. The following variations to the
protocol were made: For embryoid body (EB) production
one 25 cm2 flask of hu-iPSCs was used to seed a 96-well
plate. Cells were plated in 100 μl hES medium (20% [v/v]
knock-out serum replacement, 0.03% [v/v] fetal bovine
serum, 1× glutamax, 1× non-essential amino acids, and
1 μl / 142.86ml 2-Merceptoethanol in DME-F12 medium,
additionally supplemented on day 0 with 50 μM Y27632
and 4 ng/ml rh FGF), with a further 100 μl added at days 2
and 4. EBs were transferred into neural induction medium
(1× glutamax, 1× non-essential amino acids, 1% [v/v] N2,
and 1 μg/ml heparin in DME-F12 medium) in low
adhesion plates between days 4 and 6 depending upon
morphology. Organoids were embedded 2–4 days after
neural induction when neuroecotoderm was visible.
Matrigel embedding was done in a 6-well plate with
6 organoids per well using 30 μl of Matrigel (Roche)
and incubated in cerebral organoid media (1× glutamax, 1×
penicillin-streptomycin solution, 0.5× non-essential amino
acids, 0.5% [v/v] N2, 1 μl/4ml insulin, and 1 μl/286ml
2-Merceptoethanol in 1:1 Neurobasal:DME-F12 medium)
with 1% (v/v) B12 minus retinoic acid. On day four, orga-
noids were transferred into cerebral organoid medium with
1% (v/v) B12 plus retinoic acid for long-term culture.
Long-term agitated culture was performed in upright
25 cm2 low-adhesion flasks on an orbital shaker at 85 rpm.
Media was changed twice weekly.
Prion infections of human cerebral organoids
Brain homogenates from sporadic CJD subtypes MV1 and
MV2 were diluted into organoid maintenance media to a
final concentration of 0.1% (tissue wet weight/volume). The
inoculated media was filter sterilized through a 0.22 nitro-
cellulose filter. To ensure the infectious seeds within the in-
oculum had not been lost in the filtering process, RT-QuIC
analysis (described below) was performed on the media. Sig-
nificant RT-QuIC seeding activity was found in both MV1
and MV2 inocula (Table 1). Organoids were distributed be-
tween 6-well plates (3 organoids per well) for Prestoblue
and LDH monitoring and T25 flasks for routine mainten-
ance (6–12 organoids/flask). At the start of infection, exist-
ing media was removed from the organoids and replaced
with the inoculated media. Twenty-four hours after inocula-
tion an equivalent volume of fresh media was added to the
cultures (diluting the original inoculum 1 in 2). Organoids
were incubated for a further 3 days before a half media
exchange. A full media and culture vessel exchange was per-
formed 7 days after initial exposure. Organoids were main-
tained in agitated culture with three media changes per
week. All brain tissues used in this study were obtained on
autopsy and were therefore exempt from review by the NIH
Office of Human Subjects Research Protections.
Table 1 sCJD inoculum information
Inocula Gender Age at onset
(years)
Disease duration
(months)
Inoculum SD50/μl
MV1 M 62 14 1.58 × 105
MV2 M 57 15 8.89 × 105
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Prestoblue analysis
Prestoblue metabolism was measured as per the manufac-
turer’s instructions once weekly or as required (the same 3
organoids were monitored from start to finish of the cul-
tures). Briefly, Prestoblue reagent was diluted 1 in 10 in
organoid media. Existing organoid media was removed
and organoids were incubated in Prestoblue-containing
media for 30 mins. The metabolized Prestoblue con-
taining media was then transferred into replicate wells
for analysis. Prestoblue fluorescence was measured at
560 nm excitation and 590 nm emission in a ClarioS-
tar plate reader (BMG).
Lactate Dyhydrogenase (LDH) analysis
Extracellular LDH was measured using cytotoxicity detec-
tion kit plus [LDH] (Roche). Results shown are obtained
from the same 3 organoids as used for Prestoblue analysis.
Organoids in flasks were occasionally assayed to ensure
consistency with the plates (data not shown). Prior to the
assay start the dye solution and catalyst solution were
mixed 45:1. One hundred microliters of test or control
medium, 24 h following a complete media change, was
assayed in a 96-well tissue culture plate in triplicate by
adding 100 μl of the dye-catalyst solution and incubating
for 30 mins at room temperature. The reactions were ter-
minated by addition of 50 μl of stop solution. The plate
was mixed in a ClarioSTAR plate reader (BMG) for 10 s
before reading absorbance at 492 nm.
Immunofluorescence
Organoids were fixed and immuno-stained as described
previously [9]. FoxG1 (Abcam) and GFAP (Abcam) pri-
mary antibodies were used at a 1 in 50 dilution. Secondary
Alexafluor 488 or 555 antibodies (Invitrogen) were applied
at a 1 in 250 dilution and organoids were mounted in
Fluoromount medium (ThermoFisher) with curing at
room temperature for 24 h.
Histochemistry
Antigen retrieval was performed as previously described
[34], followed by staining using the anti-prion monoclonal
antibody 6H4 (Prionics). Astrocyte detection was per-
formed by staining with polyclonal rabbit anti-glial fibril-
lary acidic protein (anti-GFAP; Dako). Slides were also
stained for observation of overall pathology using a stand-
ard hematoxylin-eosin (H&E) protocol. All histopathology
slides were analyzed by observers blinded to the inocula-
tion groups using Aperio Imagescope software.
RT-QuIC
Real-time QuIC (RT-QuIC) assays were performed simi-
larly to those reported previously [30, 31]. Briefly, the
RT-QuIC reaction mix contained 10mM phosphate buffer
(pH 7.4), 300mM NaCl, 0.1 mg/ml hamster recombinant
PrP 90–231 (purified as described in [31]), 10 μM thiofla-
vin T (ThT), and 1mM ethylenediaminetetraacetic acid
tetrasodium salt (EDTA). Reaction mixes for culture
media seeds (from the initial inoculum and samples col-
lected throughout incubation) contained an additional
0.002% SDS in the reaction mix. Organoids were homoge-
nized by motorized pestle to 10% (w/v) in PBS and cleared
with a 2000×g 2min centrifugation. Organoid homoge-
nates were serially diluted in 0.1% SDS/PBS/N2 solution
for a final SDS concentration of 0.002% in the reaction
mix. For media seeded and organoid seeded reactions, re-
spectively, either 80 or 98 μl of reaction mix was loaded
into a black 96-well plate with a clear bottom (Nunc), and
reaction mixtures were seeded with 20 μl of media or 2 μl
of the indicated dilution of organoid homogenate for a
final reaction volume of 100 μl and the same final con-
centrations in the reaction mix as indicated above.
Plates were sealed (Nalgene Nunc International sealer)
and incubated in a BMG FLUOstar Omega plate reader
at 50 °C for 50 to 120 h with cycles of 60 s of shaking
(700 rpm, double-orbital) and 60 s of rest throughout
the incubation. ThT fluorescence measurements (excita-
tion, 450 ± 10 nm; emission, 480 ± 10 nm [bottom read])
were taken every 45min. Spearman-Kärber analyses [11]
was used to provide estimates of the concentrations of
seeding activity units giving positive reactions in 50% of
replicate reactions, i.e., the 50% “seeding doses” or SD50’s
as previously described [42].
Proteinase-K digests and Western blotting
10% organoid homogenates were treated with 5 μg/ml
Proteinase K in 1% Sarkosyl for 1 h at 37 °C with 400
rpm shaking. The reactions were stopped by incubation
with 1 μM Pefabloc for 5 min at 4 °C. Samples were then
mixed 1:1 with 2X Bolt LDS sample buffer (Invitrogen)
containing 8% β-mercaptoethanol and boiled for 10 min.
Samples were run on Bolt 4–12% Bis-Tris gels (Invitro-
gen) and transferred to PVDF membranes using the iBlot
2 transfer system (Invitrogen). PrP was detected using the
3F4 antibody (Millipore) at a 1:10,000 dilution and visual-
ized using ECL Select (Amersham) and imaged on the
iBright imaging system (Invitrogen).
Cytokine arrays
A pool of conditioned media from flasks containing 6
organoids (media from the same 6 organoids was col-
lected throughout) was collected at various time points
during the incubation period. Media was assayed for
cytokine levels using Bio-Plex Pro Human Inflamma-
tion Panel 1, 37-Plex (Biorad) as per the manufacturer’s
instructions. Cytokines below the level of detection
throughout the experiment are excluded from the
analysis.
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Data analysis
Positive pixel counts were carried out using ImageScope
v11.1.2.760 imaging software (Aperio). Statistical ana-
lysis, as indicated in figure legends, was carried out in
GraphPad Prism 7.04. Z-scores, heatmap, cluster ana-
lysis, and dendrogram of the cytokine protein secretion
by cerebral organoids were produced using the online
application Heatmapper (http://www2.heatmapper.ca/)
developed in the Wishart Research Group at the University
of Alberta [2]. The clustering method chosen was the
Average Linkage setting, and the dendrogram distance
measurement method chosen was the Pearson setting,
which establishes the distance as the absolute value of the
Pearson correlation coefficient (between 0 and 1).
Results
Organoid infections
Cerebral organoids develop mature astrocytic and oligo-
dendrocytic populations from ~ 2months, and these con-
tinue to increase in number to ~ 5months with all
organoids displaying some astrocytes by ~ 140 days [35].
Astrocytosis is prominent in prion diseases [22] and astro-
cytes have been shown to accumulate disease-associated
PrP prior to neuropathological changes [5, 10]. Therefore,
we hypothesized that these cells may be important for the
establishment of prion infection or the development of dis-
ease pathology. Human cerebral organoids were generated
from induced pluripotent stem cells (iPSCs) [20]. To allow
the cultures to develop glial populations, organoids were
grown for 5months (140 days) before commencing infec-
tions (organoid differentiation is shown in Fig. 1a with the
timeline of infections in 1B). As previously mentioned,
human prion disease phenotype and susceptibility are
influenced by the methionine/valine polymorphism at
amino acid position 129. The iPSCs used were heterozy-
gous (129M/V) for this polymorphism. To ensure optimal
opportunity for uptake of infection by the organoids, we
used brain homogenates from two sCJD patients who were
also heterozygous at codon 129. In these sporadic cases,
Proteinase-K resistant PrP had previously been glycotyped
as type 1 or 2 CJD (nomenclature as described in [32]) and
are referred to throughout as MV1 and MV2 accordingly.
The MV1 and MV2 subtypes vary in disease duration and
prevalence, with the MV1 subtype showing a generally fas-
ter disease progression but the MV2 subtype being ~ 3
times more common than the MV1 [17, 33, 36]. Our
A
B
Fig. 1 Developmental and experimental schematic. a Example phase images show organoids at early stages of development, becoming more
structured, and organoid appearance as balls of tissue in an Erlenmeyer culture flask. H&E staining at 28 days old (do) shows the complexity of
the organoids with many varied, structured domains. Immunofluorescence at 140 do confirms cortical identity (FoxG1) and shows that astrocytes
(GFAP) have begun populating the neuronal layers. Scale bars = 200 μm. b Schematic time line of organoid maturation, infection and sampling
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inocula were from cases with a similar disease duration
and age of onset (Table 1).
Organoids exhibited inoculum-related changes in health
From the start of the infections, organoids were moni-
tored for changes in their health using Prestoblue, a
non-toxic probe that produces a fluorometric/colorimetric
change within culture media in response to cell metabol-
ism, including mitochondrial metabolism and enzymes in-
volved in NADH/NADPH reactions. The MV1 inoculated
organoids initially appeared to show slowing metabolism,
but, 84 days post-infection (dpi), an almost two-fold in-
crease was measured (Fig. 2a). This increase remained
consistent for several weeks and then continued to climb
until it fluctuated in the final weeks of the study. The
MV2 inoculated organoids showed no change. At 92 dpi
increased LDH levels, indicative of cell lysis and death,
were detected in the culture media of the MV1 inoculated
organoids (but not the NBH or MV2; Fig. 2b). Therefore,
three organoids per condition were harvested for IHC
analysis at 96 dpi. The remaining organoids continued to
be monitored by Prestoblue metabolism and periodic
LDH. At 168 dpi the NBH exposed organoids showed an
increase in LDH and a decrease in Prestoblue. This could
have been indicative of the organoids starting to die from
aging and, therefore, the remaining organoids were har-
vested for IHC or protein analysis at 169 dpi.
Infected organoids were positive for RT-QuIC seeding
activity
RT-QuIC analysis was used to monitor the organoids
throughout the incubation period, by assaying culture
media for prion seeding activity. One week after the full
media exchange out of the inoculum at 7 days post
addition (14 dpi), no RT-QuIC seeding activity remained
within the media of the MV1 or MV2 organoids. For the
NBH and MV1 inoculated organoids, culture media
remained RT-QuIC negative for the duration of the
study. However, seeding activity became detectable in
the media of the organoids receiving the MV2 inoculum
at 35 dpi (Fig. 3a).
Over the first few weeks of the infections, several orga-
noids were harvested to determine the uptake of seeding
activity from the inoculum and if, or how quickly, orga-
noids could degrade the inoculum to an undetectable
level. Organoids harvested at 7 days, the end of the in-
oculum exposure period, showed seeding activity likely
resulting from remaining inoculum. MV1 organoids had
less seeding activity uptake from the inocula than MV2,
with only a low percentage of wells showing positivity
per organoid (Fig. 3b). At 14 days, seeding was detected
similarly but by 25–28 dpi all inoculated organoids
tested had cleared the original inoculum with no meas-
urable seeding activity remaining in any well. For both
inoculations seeding activity had re-appeared at 35 dpi.
By comparison organoids harvested at the end of the ex-
periment (169 dpi) showed 50% or greater positive wells
for the MV1 inoculated organoids and 100% positive for
all MV2 organoids, indicating de novo production of
seeding activity as opposed to persistence of the original
inoculum within the tissue. Overall, the MV2 inoculated
organoids showed greater seeding activity than the MV1
inoculated when harvested at 169 dpi (Fig. 3c). MV2 in-
oculated organoids had an average seeding SD50 of
2.13(±1.63) × 105 per mg of tissue, while the MV1 inocu-
lated organoids had an average SD50 of 1.69(±0.70) × 10
3
per mg of tissue (Fig. 3d) and NBH treated organoids
showed no seeding activity (Fig. 3c).
MV2 infected organoids showed protease-resistant PrP
Protease-resistant PrP is often considered a hallmark of
prion disease. Western blotting, following proteinase-K
digestion, of the organoid tissue harvested at 169 dpi
showed clear protease-resistant PrP banding in all of
A B
Fig. 2 Organoid health and viability monitoring. a Prestoblue fluorescence, indicating changes in metabolism, expressed relative to pre-
inoculated organoid metabolism. The same three organoids were monitored weekly throughout. b LDH detection in organoid culture media,
indicative of cell death or loss of membrane integrity, of the same 3 organoids as in A. Data points shown mean and SD of 3 replicate reads
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the MV2 treated organoids with an apparent shift to-
wards a di-glycosylation dominant banding pattern
with less unglycosylated PrP (Fig. 3e). Protease-resist-
ant PrP was undetectable by western blot in the MV1
treated organoids, consistent with the lower RT-QuIC
seeding activity. PrPRes could not be detected the MV1
infected organoids by western blot even following so-
dium phosphotungstic acid precipitation (data not
shown).
PrP immunostaining was altered in MV2 inoculated
organoids
During CJD, prions accumulate within the brain resulting
in different immunohistochemical appearances of PrP
from the normal protein found in individuals without
prion disease. In the cerebral organoids, total PrP immu-
nohistochemical staining was not significantly increased
as a result of infection at either 96 dpi (Additional file 1:
Figure S1) or 169 dpi (Fig. 4a/b). PrP staining was often
A B
C
E
D
Fig. 3 RT-QuIC seeding and protease resistant PrP analysis. a Media RT-QuIC monitoring throughout the duration of infection showing the number of
replicate wells positive for seeding activity at each sampling time. Each data point represents media taken from the well containing the same three
organoids in Fig. 2. Minor tick marks on the x-axis show weekly full media exchanges. b Percentage of positive RT-QuIC test wells of organoids taken
at various early time points during infection and when harvested at the conclusion on the experiment (169dpi). Each data point represents an
individual organoid tested in RT-QuIC with 4–12 replicate wells. Bars show mean and standard deviation of all organoids in each indicated group. c
RT-QuIC seeding activity of organoid homogenates diluted 10− 3 following harvest at 169 dpi. For clarity, every other datapoint was plotted. RT-QuIC
traces are displayed as averages from all organoids in each group. Error bars represent standard deviation. d SD50 values of each organoid harvested at
169 dpi and the original inoculums. Each point represents an individual organoid (or inoculum) with black lines denoting the mean and colored bars
the standard deviation. The dotted line represents the threshold of detection below which results are considered negative. e Western blots showing
PrP and protease-resistant PrP in the original brain homogenate inocula (left plate) and the organoids harvested at 169 dpi (right plate)
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seen toward the periphery of the organoid regardless of in-
oculum (Fig. 4a). However the MV2 organoids showed
areas of PrP staining internally. The internal staining of
the MV2 inoculated organoids showed areas of course,
punctate, granular PrP indicative of a sporadic CJD-like
staining pattern, while the MV1 organoids were indistin-
guishable from controls (Fig. 4c). Some artifactual staining
was additionally observed in both the controls and the
MV2 stained organoids (Fig. 4d); this was unrelated to
pathology as it was visible in the sequential no-primary
antibody control sections. These pigments are often found
within healthy organoids, visible by eye when observing
organoids in culture, and may be retinal pigment or
neuromelanin [20]. In the case of the latter, an enhanced
pigment intensity due to PrP immunoreactivity would not
be unexpected as PrP has been shown to bind to melanin
pigments [15].
Histochemistry showed no differences between sCJD
inoculated and control organoids
Vacuolation and astrogliosis are further hallmarks of prion
disease. Therefore, this was assessed by hematoxylin and
A
B
D
C
Fig. 4 Immunohistochemical staining for PrP in organoids harvested at 169 dpi. a Whole organoid images; left panels per condition show 6H4
PrP staining (brown) and right panels showing positive pixel counts (PPC), blue signifies low and yellow-orange denotes high pixel staining
intensity. Scale bars = 500 μm. b PrP positive pixel counts. Each data point represents an individual organoid with the mean indicated as a line
(Kruskal-Wallis, p = 0.132). c 6H4 PrP staining of organoid interiors. Scale bar = 50 μm and applies to left panels. Right panels are zoomed images
of the boxed regions. d PrP staining artifacts visible in NBH and MV2 treated organoids. Left panels show 6H4 PrP staining and right panels show
no-primary antibody control stains. Arrows indicate artifacts in sequential slices. Scale is as for C
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eosin (H&E) histochemistry. Organoids showed diverse
regions of organized cells with different staining inten-
sities, consistent with previous descriptions of organoid
self-organization [20, 35](Fig. 5a). At 96 dpi, vacuolation
was apparent in all three organoids given the MV1 inocula
and in two of the three MV2 treated organoids but also in
one of three of the NBH treated organoids, indicating that
vacuolation occurs from non-prion causes as a normal
event within these tissues. At 169 dpi, the NBH treated
organoids showed significant vacuolation (Fig. 5b) indicat-
ing that this parameter cannot be used as a measure of
disease pathology in these organoids.
Astrogliosis was assessed by detection of glial fibrillary
acidic protein (GFAP), an astrocyte marker. At 96 dpi,
GFAP staining appeared increased in both the MV1 and
MV2 inoculated organoids, however one of the control
NBH organoids also had a high density of astrocytes in-
dicating this may not be disease specific but reflect the
rate of maturation within the heterogenous organoids
(Fig. 6a and b). GFAP staining was highly increased 169
dpi in all organoids including controls (Additional file 1:
Figure S2). As GFAP expression is known to increase in
normal astrocytes during aging [7, 28], this traditional
marker of astrogliosis in prion disease may have limited
utility for organoid studies where cultures are aged for
long time periods.
An alternative measure of astrocyte activation is variation
in cytokine secretion indicative of neuroinflammation.
Neuroinflammation is usually mediated by microglia
and astrocytes, but, since the organoids lack microglia
(microglia differentiate from mesoderm rather than
the induced neuroectoderm), changes detected can be
Fig. 5 H&E staining. Whole organoid and 20× magnification images of H&E stains at a 96 dpi and b 169 dpi. Regions magnified are high PrP
intensity, high astrocyte intensity or both. Scale bar = 500 μm
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attributed primarily to astrocytes. We should note
here that while a recent study has shown microglia
can differentiate within cerebral organoid cultures
from residual mesoderm-derived progenitors [29], no
Iba1 positive cell staining (indicative of microglia) was
observed in our organoid cultures (data not shown).
Whilst microglia are thought to play an important role
in prion disease pathogenesis, recent research has
shown that they are not necessary for disease progres-
sion, appearing to play a protective role against patho-
genesis [6], and so we deemed their absence would not
hinder disease manifestation within the organoids. For
cytokine screening, media pools were collected at 14,
35, 68, 95, 127, 159, and 169 dpi and cluster analysis
was used to group cytokines such that the most closely
correlated detection patterns are aligned. Most detected
cytokines were highest at 14 dpi and then declined in all
organoids regardless of inoculum (Fig. 6c). However, a
cluster of cytokines with increased expression from 95 dpi
was observed in the culture medium from the MV1 inoc-
ulated organoids, including IL-8, chitinase 3-like 1, BAFF/
TNFSF13B, TNFR1 and APRIL/TNFSF13. The MV2 inoc-
ulated organoids showed a similar increase in TNF-R1
and APRIL/TNFSF13 but otherwise showed little change
A
B C
D
Fig. 6 Astrocyte changes during infection. a Whole organoid images at 96 dpi; left panels per condition show GFAP staining (pink) and right
panels showing positive pixel counts (PPC), blue signifies low and yellow-orange denotes high pixel staining intensity. Scale bars = 500 μm. b
GFAP positive pixel counts of the 96 dpi whole organoid images. Each data point represents an individual organoid with the mean indicated as a
line (Kruskal-Wallis, p = 0.196). c Heatmap and dendrogram cluster analysis of cytokine detection in culture medium at 14, 35, 68, 95, 127, 159, 169
dpi. Black triangles showing increasing time from inoculation. Data points are generated using media pools from 6 individual organoids. Grey
boxes indicate cytokine concentrations below the limits of detection. d Concentrations of Chitinase 3-like 1 in culture medium over time. #
readings exceeded the accurate range of detection for the assay
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from NBH inoculated organoids. Notably, the increase in
chitinase 3-like 1 secretion measured for the MV1 inocu-
lated organoids was almost 30-fold, with two samplings
(at 127 and 159 dpi) showing readings in excess of the
accurate limit of detection.
Discussion
Herein, we have demonstrated that iPSC-derived human
cerebral organoid cultures can be used to model prion
transmission, propagation and limited disease pathology.
We show that two different sporadic CJD inocula affect
the same underlying organoid line differently, supporting
that the prion seed greatly influences the disease pheno-
type in genetically identical human cells. Our data also
indicated that the underlying cell type itself influences
the protease-resistant prions that are formed; in all of
the MV2 organoids, a shift from the monoglycosylation
dominant banding pattern of the sCJD inoculum to
diglycosylation dominant indicates that the prions have
adapted as they propagated within the organoids.
The MV2 inoculum produced more overt measures of
infection in the organoids than the MV1 inoculum, with
clear protease-resistant PrP and PrP tissue deposition.
The MV1 inoculated organoids generated de novo seed-
ing activity but did not show these traditional hallmarks
of prion infection. It is probable that the MV1 PrP seed-
ing the RT-QuIC reaction was close to the limits of de-
tection, and consequently too low to be detected by
traditional techniques. Alternatively, the newly synthe-
sized MV1 prions might be protease sensitive. The pres-
ence of protease sensitive PrP is a possibility since as
much as 90% of the mis-folded PrP in CJD brain tissue
has been reported to be protease sensitive [37], and in
mouse models of prion infection, PrP mutations that
cause accumulation of protease sensitive prions result in
a highly neurotoxic species [8]. Preliminary consider-
ation of insoluble PrP within the organoids indicated
that it may be present in some MV1 infected organoids
(data not shown), therefore the role of protease sensitive
PrP warrants further investigation in future studies. Des-
pite the lack of hallmark indicators of PrP infection, the
MV1 inoculum demonstrated more influence on health
parameters. We can speculate that this could be a prop-
erty of the MV1 prions; potentially, a more neurotoxic
phenotype might correlate with the shorter median clin-
ical course often observed in MV1 sCJD, typically 4–5
months as compared with ~ 11–17months in MV2 sCJD
[17, 33, 36]. However, whether this is related to subtype
or an inoculum-specific effect will not be answerable
until a greater number of inocula have been screened
within this system.
Other factors may have influenced the differences ob-
served between the two inoculas. Prions spread from cell
to cell by a number of methods including tunneling
nanotubules and exosomal release [12, 41, 47]. Using
mouse prion strains it has been shown that the amount of
infectivity released through the exosomal pathway is
highly strain dependent [1], and this may also be true for
the sCJD subtypes. The prions released into the media
through the exosomal pathway may be much lower for
the MV1 inoculated organoids than the MV2, resulting in
a lack of detection within the media and slower propaga-
tion of prions through the tissue. Secretion of the MV2
prions into the culture medium may also have aided
spread between the organoids in each culture vessel. The
lack of detectable seeding activity from the media of the
MV1 inoculated organoids is most likely due to released
prions being below the threshold of detection.
Cellular heterogeneity may also contribute to the dif-
ference between the organoids inoculated with the MV1
and MV2 prions. During the formation and development
of the organoids, various cell populations are patterned
[43]. Prion subtypes often exhibit different histopatho-
logical lesions within different brain regions. The hetero-
geneity of the organoids may result in a preference for
uptake of an inoculum that attacks the specific neuronal
populations developed within the organoid. MV1 infec-
tion levels may be lower as organoids contain less neu-
rons capable of propagating MV1 prions or because
MV1 prions are more toxic to these populations, causing
their death before they have propagated new prions.
Organoid technology is continuing to progress, such that
organoids can be stimulated to differentiate in specific
directions, such as dorsal or ventral forebrain and cere-
bellum [27, 40]. This utility could prove highly valuable
in understanding why different prion subtypes preferen-
tially attack specific brain regions. A further exciting de-
velopment in organoid technologies is the merging of
organoids composed of different brain regions and the ex-
change of cells that results [3, 43]. This could be adapted
to provide valuable information on the spreading of prions
from cell to cell within the human brain.
While the MV1 uptake and propagation was clearly
lower than observed for the MV2, the MV1 infected orga-
noids showed changes in health as a result of exposure to
the inoculum, including increased metabolism, LDH re-
lease and cytokine release. Chitinase 3-like 1, Chi3L1 or
YKL-40, is an inflammatory cytokine primarily produced
in adult astrocytes [46], which can induce death of neu-
rons and oligodendrocytes [23, 45]. Chi3L1 has previously
been reported to be increased in MM1 and VV2 sCJD
brain [24]. MV1 and MM1 sCJD are grouped as the same
subtype due to the similarities in pathology of these two
diseases [13, 32], therefore the increase in this cytokine in
the MV1 inoculated organoids is consistent with expected
in vivo changes. The lack of Chi3L1 change in the MV2
organoids is unclear but detection may have increased had
these organoids been cultured for longer.
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Infection of hu-iPSC derived neuronal cultures has been
attempted previously using both ‘normal’ cells and cells
carrying the prion Y218N mutation [26]. These infections
were unsuccessful, but there may be several reasons that
explain the difference from our own study. First, the
hu-iPSCs infected in the Y218N study were differentiated
as monolayers, which may lose infected cells over serial
passages. Second, the authors followed the cultures until
77–79 dpi, but our model had not shown PrP deposition
in the tissues at 96 dpi. Therefore, longer incubations may
be required to demonstrate infection, which may or may
not be possible in the previous model.
Our model demonstrates that cerebral organoids can
propagate prion infection from sCJD sources, and that dif-
ferent sCJD subtypes may manifest differently within the
same underlying cell. Whilst this latter point is currently
being validated, requiring a greater number of inocula to be
screened beyond the two tested herein, the capability of
organoids differentiated from the same underlying iPSCs to
differentiate distinct sCJD subtypes based on their bio-
logical properties may be of immense value for understand-
ing the pathologies caused by different human prions.
Conclusion
Human cerebral organoids are a promising new system for
modelling prion disease in cell culture. Organoids take up
prion infection, influenced by the prion seed to which they
are exposed, and generate new seeding activity. Further-
more, they can produce glycosylated protease-resistant PrP
and PrP deposition. We acknowledge that the cerebral orga-
noids have clear limitations; they are highly heterogenous,
not vascularized and they may lack non-neuronally derived
cells of the brain such as epithelial cells and microglia. Des-
pite these limitations, these cultures represent the closest in
vitro cell model to human brain currently available and offer
the first human three-dimensional model of prion disease.
Their use holds promise for the investigation of different
subtype pathologies, for investigation of how prions spread
throughout the brain and for trialing putative therapeutics
in a human tissue background.
Additional file
Additional file 1: Figure S1. Whole organoid PrP staining at 96dpi.
Upper panels display whole organoid images; left panels per condition
show 6H4 PrP staining (brown) and right panels showing positive pixel
counts (PPC), blue signifies low and yellow-orange denotes high pixel
staining intensity. Scale bars = 500 μm. Lower graph shows PrP positive
pixel counts. Each data point represents an individual organoid with the
mean indicated as a line. Figure S2. GFAP staining of organoids. A. Panels
display whole organoid (left) and 20x magnified images of regions of
interest (right) of organoids harvested at 169 dpi. B. Positive pixel counts
(PPC) at 96 and 169 dpi, blue signifies low and yellow-organe denotes
high pixel staining intensity. Scale bars = 500 µm. C. GFAP positive pixel
count quantification at 169 dpi. Each data point represents an indevidual
organoid with the mean indicated as a line. (DOCX 1790 kb)
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